Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.75 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 4/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | TYK2 | P29597 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425101 | 0.86 | PTGS2 (1.00) | PTGS2ALDH1A1GAACA1CA9 | |
| Hydrochloric Acid SCHEMBL9017504 | 0.84 | PTGS2 (0.96) | PTGS2ALDH1A1GAACA1CA9 | |
| SCHEMBL2986200 | 0.84 | ALDH1A1 (0.83) | PTGS2HTTALDH1A1GAACA1 | |
| SCHEMBL28871751 | 0.82 | PTGS2 (0.70) | PTGS2ALDH1A1GAACA1CA9 | |
| SCHEMBL28959086 | 0.82 | ALDH1A1 (0.60) | PTGS2HTTALDH1A1GAACA1 | |
| SCHEMBL28871809 | 0.82 | ALDH1A1 (0.60) | PTGS2ALDH1A1GAACA1CA9 | |
| SCHEMBL28871725 | 0.82 | ALDH1A1 (0.60) | PTGS2HTTALDH1A1GAACA1 | |
| SCHEMBL946432 | 0.81 | HTT (1.00) | HTTALDH1A1GAACA1CA9 | |
| SCHEMBL9785877 | 0.81 | PTGS2 (0.81) | PTGS2ALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL28871731 | 0.81 | ALDH1A1 (0.58) | PTGS2ALDH1A1GAAKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325385-A1 | ANTI-TUMOR PHARMACEUTICAL COMPOSITION COMPRISING EZH2 INHIBITOR AND SCD1 INHIBITOR AND USE THEREOF | PEKING UNIVERSITY THIRD HOSPITAL (CN) | 2024-10-03 | — | — | US | claimed |
| WO-2024173715-A1 | ANTIFUNGAL COMPOSITIONS AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-08-22 | — | — | WO | claimed |
| WO-2023108563-A1 | ANTI-TUMOR PHARMACEUTICAL COMPOSITION COMPRISING EZH2 INHIBITOR AND SD1 INHIBITOR AND USE THEREOF | 北京大学第三医院（北京大学第三临床医学院） | 2023-06-22 | — | — | WO | claimed |
| US-20230126711-A1 | ENTERIC NITRERGIC NEURONS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-27 | — | — | US | claimed |
| EP-4125945-A1 | ENTERIC NITRERGIC NEURONS AND METHODS OF USING THE SAME | The Regents of the University of California (US) | 2023-02-08 | — | — | EP | claimed |
| CN-114177299-A | Antitumor pharmaceutical composition containing EZH2 inhibitor and SCD1 inhibitor and application thereof | 北京大学第三医院（北京大学第三临床医学院） | 2022-03-15 | — | — | CN | claimed |
| US-20210137934-A1 | METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-05-13 | — | — | US | claimed |
| WO-2018170316-A1 | METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-09-20 | — | — | WO | claimed |
| US-4758312-A | Adding colorless electrochemically active compound having positive reduction potential | NALCO CHEMICAL COMPANY (US) | 1988-07-19 | — | — | US | claimed |
| EP-4687925-A1 | THYMIC CELL COMPOSITIONS AND METHODS OF MAKING | Thymmune Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12492382-B2 | Blood type O Rh—hypo-immunogenic cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250283051-A1 | CELLS DIFFERENTIATED FROM IMMUNOENGINEERED PLURIPOTENT CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4585223-A2 | TRANSPLANTED CELL PROTECTION VIA INHIBITION OF POLYMORPHONUCLEAR CELLS | The Regents of the University of California (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12351819-B2 | Method for removing undifferentiated pluripotent stem cells | ACADEMIA SINICA (TW) | 2025-07-08 | — | — | US | disclosed |
| EP-2068873-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | Pharma 2100 (DK) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008031440-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | PHARMA 2100 (DK) | 2008-03-20 | — | — | WO | disclosed |
| CN-1826335-A | Process for producing 1,2, 4-triazole compound and intermediate therefor | FUJIYAKUHIN CO LTD (JP) | 2006-08-30 | — | — | CN | disclosed |
| US-4758312-A | Adding colorless electrochemically active compound having positive reduction potential | NALCO CHEMICAL COMPANY (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0237738-A2 | Method for in situ corrosion detection using electrochemically active compounds | NALCO CHEMICAL COMPANY (US) | 1987-09-23 | — | — | EP | disclosed |
| US-4683035-A | Method for in situ corrosion detection using electrochemically active compounds | NALCO CHEMICAL COMPANY (US) | 1987-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351819-B2 | Method for removing undifferentiated pluripotent stem cells | ALPG, UGGT1, GYPA | PTGS2 1871/4885HTT 2397/4885ALDH1A1 70/4885 |
| US-20230126711-A1 | ENTERIC NITRERGIC NEURONS AND METHODS OF USING THE SAME | PROX1, MYH2, NOS2 | PTGS2 105/4885HTT 369/4885ALDH1A1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.